Similarly, TGF-β/TGF-β receptor inhibitors are also considered as potential targets for breast cancer therapy alongside doxorubicin, as additional studies have confirmed that TGF-β blockade improves the distribution and efficacy of doxorubicin [54,55]. Here, TGFB1 is linked to breast cancer.